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Abstract In order to provide a basis for clinical treatment
decisions, we explored whether there was a correlation
between the expression of COX-2 and P300 and clinical
factors in a group of patients with laryngeal squamous cell
carcinoma (LSCC). A retrospective analysis of clinico-
pathological data was conducted in 80 patients with LSCC
who presented between January 1997 and December 1998.
An immunohistochemistry tissue microarray was con-
ducted of 80 surgically resected LSCC and 20 adjacent
normal tissue specimens. Survival analysis and Kaplan–
Meier curves were used to compare the effects of clinico-
pathological factors on survival. The Cox model was
applied for multivariate analysis. The expression level of
COX-2/P300 in LSCC tissues and adjacent normal tissues
were 47.5/50.0 versus 0.0/15.0 %. The expression of COX-
2 and P300 was correlated with higher T category, N cat-
egory, clinical staging, histological grade and recurrence
(P \ 0.05). P300 expression was correlated with COX-2
expression (P \ 0.05). Univariate survival analysis showed
that P300, COX-2, N category, clinical staging and recur-
rence factors were closely correlated with unfavorable
survival (P \ 0.05). Multivariate analysis showed that
COX-2 expression, histological grade and recurrence were
independent prognostic factors for LSCC. High expression
levels of COX-2 and P300 indicated poor survival out-
comes for patients with LSCC.
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Laryngeal carcinoma is a common head and neck tumor.
The larynx is an important organ for pronunciation,
breathing and swallowing and patients with laryngeal
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carcinoma can develop dysphonia, dysphagia and dyspnea.
To achieve the best chance of a cure, the larynx is usually
sacrificed during the surgical management of laryngeal
squamous cell carcinoma (LSCC), and complete laryn-
gectomy is performed for advanced stage cases with con-
sequent radical changes to physiological and psychological
function. Within the past 20 years, surgical techniques
have improved, and combined radio- and chemotherapy
offers the opportunity to preserve the larynx. However, the
survival rate for advanced stage cases remains low. Further
research on the molecular biology mechanisms that
underlie LSCC has great importance in improving out-
comes for this disease.
There are two cyclooxygenase (COX) enzymes, COX-1
and COX-2. COX-1 is a housekeeping gene that is
expressed constitutively in most tissues [1]. In contrast,
COX-2 is an immediate-early response gene that is induced
by a variety of stimuli [2]. Multiple studies have confirmed
that high expression levels of COX-2 were closely related
to the development and prognosis of many tumors [3–5].
P300 proteins play a central role in the regulation of
gene transcription. They are transcriptional coactivators
that can integrate multiple signal-induced pathways and
coordinate gene expression, acting as crucial scaffolds for
the formation of transcriptional initiation complexes [6].
The oncogenic role of P300 has been reported in lung,
colorectal, breast and prostate cancers, and its overex-
pression is indicative of a poor prognosis [7–10]. A recent
study has shown that changes in the expression of P300 are
associated with esophageal squamous cell carcinoma
(ESCC) invasion and metastasis in vitro [11]. However, the
significance of P300 expression for the prognosis of LSCC
has not been elucidated. P300 is closely correlated with
variety of acetylated gene promoters. Some studies have
shown that P300 is related to the acetylation of the COX-2
gene promoter. Therefore, the regulation of P300 expres-
sion could inhibit COX-2 expression and consequent
tumorigenesis [12].
Our study retrospectively investigated the role of P300
and COX-2 expression in LSCC with the use of a tissue
microarray method and analyzed the correlation between the
expression of these proteins and clinicopathological fea-
tures. This study would help to provide a theoretical basis for
the further clinical prevention and treatment of LSCC.
Materials and methods
Clinical data
The inclusion criteria for cases were as follows: (1) patients
hospitalized with laryngeal cancer in Sun Yat-sen univer-
sity cancer center between January 1997 and December
1998; (2) the pathological diagnosis was squamous cell
carcinoma, including well, moderately and poorly differ-
entiated tumors; (3) radical surgery was performed for
cancer treatment, including partial/total laryngectomies
and neck dissection; (4) the patients did not receive asso-
ciated radiotherapy, chemotherapy or surgery prior to their
hospitalization; (5) the paraffin section was well preserved
and (7) integrated follow-up data were available.
All clinical data from the 80 cases with LSCC are
summarized in Table 1. All cases were restaged according
to the American Joint Committee on Cancer (AJCC) TNM
Staging System for the Larynx (7th ed., 2010). Tumor size
and the presence of neck node metastases were determined
Table 1 The relationship between the expression of COX-2 and
P300 and clinicopathological factors
Factor COX-2 P300
? - RR P ? - RR P
Gender
Male 35 40 0.065 0.569 37 38 0.052 0.649
Female 3 2 3 2
Age
\60 years 21 21 0.025 0.787 22 20 0.021 0.856




11 28 0.396 0.000 13 26 0.349 0.001
Moderately
differentiated
16 11 16 11
Poorly
differentiated
11 3 11 3
T category
T1 ? T2 20 33 0.300 0.007 22 31 0.258 0.021
T3 ? T4 18 10 18 9
N category
N0 28 41 0.343 0.002 30 39 0.323 0.003
N? 10 1 10 1
Clinical staging
I ? II 18 32 0.297 0.007 20 30 0.258 0.021
III ? IV 20 10 20 10
Anatomic subsite of tumor
S 12 4 0.275 0.013 10 6 0.125 0.269
G 36 28 30 34
Recurrence
Yes 19 4 0.447 0.000 18 5 0.359 0.001
No 19 38 22 35
P300
? 33 7 0.701 0.000
- 5 35
Bold values indicate statistical significance (P \ 0.05)
S superglottic, G glottic
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by clinical, electronic fiber laryngoscopy and radiological
examinations, including CT and MRI scans. The possible
presence of distant metastasis was assessed by chest X-ray
films, bone scintigraphy or ultrasound examinations.
Tissue microarray construction
Tumor tissue samples from 80 cases were collected, fixed
in formalin\, and embedded in paraffin. Hematoxylin and
eosin-stained slides were reviewed by two senior patholo-
gists to define representative tumor regions. Two targeted
core samples of each specimen were obtained using a tissue
array instrument (MiniCore instruments; Alphelys, Plaisir,
France).
Tissue cylinders with a diameter of 10 mm were pun-
ched and arrayed on a recipient paraffin block. Sections
(5 lm) of the tissue array (recipient) block were cut and
placed on glass slides. After the exclusion of cores with
inadequate tissue after sectioning and tissue transfer, the
final immunohistochemical analyses included core biopsies
from 80 LSCC cases. Among the 80 cases, 20 cases of
formalin-fixed paracancerous normal laryngeal tissues,
which served as controls, were included according to the
method described above.
Immunohistochemistry and assessment
Immunohistochemical staining was performed using the
tissue microarray sections that were rehydrated by means
of a graded alcohol series. Endogenous peroxidase activity
was blocked with 0.3 % hydrogen peroxide for 15 min. For
antigen retrieval, the tissue microarray slides were boiled
in Tris (hydroxymethyl) aminomethane-EDTA buffer (pH
8.0) in a pressure cooker for 20 min. Nonspecific binding
was blocked with 10 % normal goat serum for 20 min. The
tissue microarray slides were incubated with mouse
monoclonal anti-KAT3B/P300 antibody (ab54984, 3 lg/
mL dilution; Abcam, Cambridge, MA, USA) and mouse
monoclonal anti-COX-2 antibody (sc-166475, 1:120, Santa
Cruz Biotechnology, Inc.) for 12 h at 4 C in a moist
chamber. Subsequently, the slides were sequentially incu-
bated with biotinylated rabbit anti-mouse immunoglobulin
antibody at a concentration of 1:100 for 30 min at 37 C
and then with a streptavidin-peroxidase conjugate for
30 min at 37 C with diaminobenzidine as the chromogen
substrate. The nucleus was counterstained using Meyer’s
hematoxylin. The negative control was obtained by
replacing the primary antibody with PBS.
All slices were reviewed by two experienced patholo-
gists independently. Information on cell shape, atypia,
interstitial constituents and the invasion of surrounding
tissues was collected. The assessment of immunohisto-
chemical stains of the tissue microarray slices were
interpreted as either positive or negative; more than 10 %
of cells that stained brown particles in nests were consid-
ered positive (Fig. 1).
Follow-up and statistical analysis
Information was collected on the 80 patients with LSCC by
letter, telephone and outpatient follow-up visits. Follow-up
continued to February 2012; the follow-up period was
defined as from the date of the definitive diagnosis to the
final visit or time of death. All data were analyzed using
SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Cor-
relation analyses used the Chi-square test. Kaplan–Meier
survival curves were generated and log-rank tests were
used to evaluate the differences between overall survival
(OS) rates. A Cox regression model was applied for the
multivariate analysis. The boundary for statistical signifi-
cance was P \ 0.05.
Results
Clinical features
The clinical data of 80 patients are summarized in Table 1.
Overall, 75 males and five females were included in this
study. Their ages ranged from 36 to 80 years, with a
median of 60 years. The most commonly affected site was
the glottic portion (n = 64; 80.0 %), followed by the
supraglottic portion (n = 16; 20.0 %). All of the 80
patients underwent surgical resection without chemother-
apy, and 46 cases received postoperative radiotherapy.
The patients had a survival time that ranged from 4 to
207 months (median, 73 months). Death occurred from the
tumor in 47 cases, and the other 33 cases are still alive.
Two patients developed distant metastases, one to the lung
and the other to the brain.
Therapeutic regimen
The treatment regimens were as follows: cordectomy
(n = 23), cordectomy combined with radiotherapy (n = 16),
partial laryngectomy (n = 6), partial laryngectomy com-
bined with radiotherapy (n = 8), partial laryngectomy and
neck dissection (n = 4), total laryngectomy (n = 13), total
laryngectomy combined with radiotherapy (n = 1), total
laryngectomy and neck dissection combined with radio-
therapy (n = 7), primary radiotherapy and chemotherapy
combined with neck dissection (n = 2).
The dose of radiotherapy was 40–68 Gy, which was
delivered to the primary site in 27 cases, the neck in 2 cases
and both the primary and neck regions in 5 cases. The
operation margins were positive in eight cases and negative
Eur Arch Otorhinolaryngol (2013) 270:1009–1017 1011
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in 72 cases. Eight patients with positive margins were
given postoperative radiotherapy, while 26 cases received
radiotherapy because the lesions were extensive, although
the margins were negative.
Prognosis and follow-up
The percentage of COX-2 and P300 expression in LSCC
tissue were 47.5 and 50.0 %, respectively. Their expression
in the adjacent normal tissues were 0.0 and 15.0 % for both
(Figs. 1, 2). The expression levels of COX-2 and P300
were correlated with T stage, N stage, clinical stage,
histological grade and recurrence (P \ 0.05). COX-2
expression was correlated with P300 expression (P \ 0.05)
(Table 1). Univariate survival analysis showed that COX-2
and P300 expression levels, N category, clinical staging
and recurrence factors were closely correlated with unfa-
vorable survival (P \ 0.05) (Table 2) (Fig. 3). Multivariate
analysis showed that COX-2 expression, histological grade
and recurrence were independent prognostic factors for
LSCC (P \ 0.05) (Table 3).
Discussion
Laryngeal squamous cell carcinoma is one of the most
common head and neck malignant tumors. We have
observed that some patients that have the same histological
grade and clinical stage have obviously different progno-
ses. Therefore, the search for biological indicators that are
closely related to clinicopathological factors is very
important.
COX-2/P300 expression levels correlate with invasion
and lymph node metastasis in LSCC
Recently, many studies have confirmed that COX-2 plays a
role in many molecular tumorigenic mechanisms. For
Fig. 1 COX-2 expression
according to immunohistochemical
staining of LSCC samples. a,
b A laryngeal squamous cell
carcinoma (LSCC) case
demonstrating a high expression
level of COX-2 (arrow)
detected in the cytoplasm of
carcinoma cells (magnification:
a 9100; b 9400); c, d Negative
expression level of COX-2
detected in LSCC
(magnification: c 9100;
d 9400); e, f Negative
expression level of COX-2
detected in adjacent normal
tissue of LSCC (magnification:
e 9100; f 9400)
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example, COX-2 can rapidly induce a response to tumor-
promoting cytokines and growth factors through patho-
logical pathways that affect mitosis, cell adhesion and
immune monitoring. COX-2 has been therefore implicated
in promoting tumorigenesis and cancer progression [3, 13].
Morita et al. [3] indicated that COX-2 promotes tumor
lymphangiogenesis and lymph node metastasis in oral
squamous cell carcinoma. Takatori et al. [4] investigated
228 cases of esophageal carcinoma patients and found
that cases with COX-2 overexpression had deeper tumor
invasion, more advanced clinical staging, poorer histo-
logical differentiation and poorer prognoses than those
with low or no expression of COX-2. Sayar et al. [14]
reported that the overexpression of COX-2 was a
Fig. 2 P300 expression
according to immunohistochemical
staining of LSCC samples. a,
b A laryngeal squamous cell
carcinoma (LSCC) case
demonstrating a high expression
level of P300 (arrow) detected
in the nuclei of carcinoma cells
(magnification: a 9100;
b 9400); c, d Negative
expression level of P300
detected in LSCC
(magnification: c 9100;
d 9400); e, f Positive
expression level of P300
(arrow) detected in adjacent
normal tissue of LSCC
(magnification: e 9100;
f 9400); g, h Negative
expression level of P300
detected in adjacent normal
tissue of LSCC (magnification:
g 9100; h 9400)
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potentially important factor in the evolution of carcino-
genesis in precancerous lesions and might be an indicator
of carcinoma development. Sun et al. [15] found that the
patients with pathological grade III and IV disease
showed a higher level of COX-2 expression than those
with grade I and II disease. The rate of COX-2 overex-
pression was higher in the cervical lymph node metastasis
group than in the non-metastasis group. The expression of
COX-2 has been closely associated with microvessel
density (MVD) in LSCC.
P300, which is also known as KAT3B/EP300, is a
transcriptional coactivator of various transcription factors.
It is involved in a wide array of cellular activities, such as
DNA repair, cell growth, differentiation, apoptosis and
migration [16–19]. Liao et al. [20] confirmed that T staging
and N staging were positively correlated with P300
expression. Li et al. [21] investigated the clinicopatholog-
ical data of 240 patients with resectable esophageal carci-
noma and confirmed that P300 overexpression was closely
associated with poorly differentiated tumors and a higher
TNM stage.
Our study showed that high levels of COX-2 and P300
were present in the patients with lymph node metastasis,
advanced stage and poorly differentiated tumors than in
those with no lymph node metastases, early staging and
well or moderately differentiated tumors (P \ 0.05). We
hypothesize that COX-2 and P300 overexpression are
correlated with invasion and metastasis in LSCC. However,
we did not confirm that COX-2 and P300 were correlated
with the anatomic subsite of the tumor (P [ 0.05); COX-2/
P300 overexpression rates were higher in the superglottic
site group than in the glottic site group (75.0/62.5 vs. 56.3/
46.8 %). Further research need to be carried out to confirm
this finding.
The relationship between COX-2/P300 expression
and LSCC recurrence
Recurrence is an important factor that influences the
prognosis of LSCC [22]. Grudzinski et al. [5] reported
that the cases of breast cancer with COX-2-positive
expression had shorter recurrence intervals of primary
tumor than those with negative COX-2 expression, and
COX-2 overexpression was an independent prognosis
factor for primary recurrence. Meyer et al. [23] reported
that COX-2 expression predicted a high risk of disease
recurrence in patients with localized primary stage p T1-2
malignant melanoma. Isharwal et al. [10] detected that
P300 was the highest risk marker for recurrent prostate
carcinoma.
Our study showed that the recurrence rate of the group
was 28.8 %, and COX-2 and P300 expressions were clo-
sely correlated with recurrence (P \ 0.05). The COX-2/
P300 expression rates were higher in the recurrence group
than in the no recurrence group (82.6/78.3 vs. 33.3/
38.6 %). From one aspect, this indicated that the COX-2
and P300 positive expression group was more susceptible
to recurrence than the negative expression group. There-
fore, we proposed that we should perform more close fol-
low-up and adjuvant radiotherapy in cases with positive
Table 2 Univariate survival analysis of 80 cases of LSCC
Factor N v2 P
Gender
Male 75 0.218 0.640
Female 5
Age
\60 years 42 1.048 0.306
C60 years 38
Medical history
\12 months 61 -0.160 0.155
C12 months 19
Histology grade




T1 ? T2 53 3.517 0.061
T3 ? T4 27
N category
N0 69 10.919 0.001
N? 11
Clinical staging
I ? II 50 4.526 0.033
III ? IV 30
Anatomic subsite of tumor
S 16 1.294 0.255
G 64
Recurrence
Yes 23 22.833 0.000
No 57
Resection margin
Positive 8 3.105 0.078
Negative 72
COX-2
Positive 38 45.788 0.000
Negative 42
P300
Positive 40 23.777 0.000
Negative 40
Bold values indicate statistical significance (P \ 0.05)
S superglottic, G glottic
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COX-2 and P300 expression. However, this hypothesis
requires further animal experiments and clinical trials to
prove the assumption. Even though three cases (3/20) of
adjacent normal tissue were positive P300 expression, the
case was not enough and the real clinical significance need
to be further investigated.
Fig. 3 Kaplan–Meier survival
analysis of clinicopathological
factors associated with COX-2
and P300 expression in patients
with LSCC (log-rank test).
a Overall survival of the
patients with different T
categories; b overall survival of
the patients with different N
categories; c overall survival of
the patients with different
clinical staging; d overall
survival of the patients with or
without recurrence; e overall
survival of the patients with or
without P300 expression;
f overall survival of the patients
with or without COX-2
expression
Eur Arch Otorhinolaryngol (2013) 270:1009–1017 1015
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The relationship between COX-2/P300 expression
and prognosis in LSCC
Most studies have reported that P300 and COX-2 overex-
pression are poor prognostic factors [4, 21, 24]. Chang
et al. [24] investigated 82 cases of oropharyngeal squamous
cell carcinoma and detected that cases with COX-2
expression had a worse prognosis than those with negative
COX-2 expression. Li et al. [21] reported that esophageal
carcinoma cases with P300 overexpression had a worse
survival rate than those with lower expression (mean sur-
vival times were 56.9 and 80 months, respectively).
However, different opinions exist regarding COX-2. Park
et al. [25] showed that COX-2 expression was positive in
493/861 (57.3 %) of invasive tumors, but this marker alone
was not related to survival outcome. However, [COX-2(?)/
Ki-67(?)] tumors were significantly associated with unfa-
vorable factors and worst survival outcomes, but the
[COX-2(?)/Ki-67(-)] tumors showed significantly favor-
able parameters and better outcomes. COX-2(-)/Ki-
67(any) showed an intermediate prognosis. Atula et al. [26]
reported that COX-2 expression does not have any prog-
nostic significance in advanced oral and pharyngeal squa-
mous cell carcinoma, and therefore further studies should
be carried out to verify the role of COX-2 in cancer
invasion and metastasis.
Some scholars have proposed that the inhibition of
P300 can prevent tumorigenesis [27, 28]. Xiao et al. [12]
found that quercetin suppresses COX-2 expression
mainly by inhibiting the P300-mediated acetylation of
transactivators in human breast cancer cells. Takeuchi
et al. [29] found that P300 expression reduced doxoru-
bicin resistance in bladder cancer. These results indicate
that P300 may be a promising molecular therapeutic
target.
As P300 expression was positively related to COX-2
expression (P \ 0.05), P300 factor was not introduced into
the Cox regression model. Our study showed that COX-2
overexpression was an independent high-risk factor for
prognosis, and the average survival time in COX-2 or P300
positive group was lower than that in COX-2 or P300
negative group (46/60 vs. 164/155 months). Our results
were similar to other reports. According to our present
data, we propose that we should pay more attention to the
patients with COX-2 or P300 expression, with more radical
resections and closer follow-up.
Our team has investigated the influence of COX-2 on a
human tongue carcinoma cell line and found that siRNA-
COX-2 significantly inhibited its proliferation and invasion
[30]. However, the molecular interactions between P300
and COX-2 still require further study.
Conclusion
The expression levels of COX-2 and P300 were increased
in LSCC tissues. High expression levels of COX-2 and
P300 indicated poor survival outcomes for patients with
LSCC. The interactions between COX-2 and P300 in
LSCC require further investigation, but COX-2 and P300
may become biological targets in the treatment of LSCC.
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Table 3 Results of the Cox regression model for the analysis of laryngeal squamous cell carcinoma prognosis versus clinicopathological factors
Factor B SE Wald df Sig. Exp(B) 95.0 % CI Exp(B)
Low High
Gender -0.774 0.784 0.976 1 0.323 0.461 0.099 2.143
Age 0.034 0.018 3.514 1 0.061 1.035 0.998 1.073
Medical history -0.041 0.025 2.692 1 0.101 0.960 0.914 1.008
Histology grade -0.582 0.288 4.099 1 0.043 0.559 0.318 0.982
T category 0.204 0.726 0.079 1 0.779 1.226 0.295 5.090
N category 0.075 0.651 0.013 1 0.908 1.078 0.301 3.865
Clinical staging 0.052 0.378 0.019 1 0.890 1.054 0.502 2.212
Anatomic subsite of tumor 0.767 0.531 2.084 1 0.149 2.153 0.760 6.096
Recurrence -1.118 0.386 8.375 1 0.004 0.327 0.153 0.697
Resection margin 1.480 0.779 3.610 1 0.057 4.393 0.954 20.223
Treatment modality 0.308 0.303 1.032 1 0.310 1.361 0.751 2.465
COX-2 2.413 0.449 28.835 1 0.000 11.164 4.628 26.931
Bold values indicate statistical significance (P \ 0.05)
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123
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin
endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol
Chem 271(52):33157–33160
2. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T,
Inoue H, Dannenberg AJ (1997) Retinoids suppress epidermal
growth factor-induced transcription of cyclooxygenase-2 in
human oral squamous carcinoma cells. Cancer Res 57(14):2890–
2895
3. Morita Y, Hata K, Nakanishi M, Nishisho T, Yura Y, Yoneda T
(2012) Cyclooxygenase-2 promotes tumor lymphangiogenesis
and lymph node metastasis in oral squamous cell carcinoma. Int J
Oncol 41(3):885–892
4. Takatori H, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y,
Setoyama T, Sasaki K, Tamotsu K, Owaki T, Ishigami S, Aikou
T (2008) Cyclooxygenase-2 expression is related to prognosis in
patients with esophageal squamous cell carcinoma. Eur J Surg
Oncol 34(4):397–402
5. Grudzinski M, Cambruzzi E, Lahude E, Savaris RF, Pedrini JL,
Zettler CG (2006) Cox-2 and CD105 expression in breast cancer
and disease-free survival. Rev Assoc Med Bras 52(4):275–280
6. Chan HM, La Thangue NB (2001) p300/CBP proteins: HATs for
transcriptional bridges and scaffolds. J Cell Sci 114(Pt
13):2363–2373
7. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG
(2007) Roles of CREB-binding protein (CBP)/p300 in respiratory
epithelium tumorigenesis. Cell Res 17(4):324–332
8. Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S,
Kimura S, Kimura W (2007) Expression of HDAC1 and CBP/
p300 in human colorectal carcinomas. J Clin Pathol 60(11):1205–
1210
9. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha
EA, Powe DG, Macmillan RD, Ellis IO, Stylianou E (2008) The
prognostic significance of steroid receptor co-regulators in breast
cancer: co-repressor NCOR2/SMRT is an independent indicator
of poor outcome. Breast Cancer Res Treat 110(3):427–437
10. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW,
Veltri RW (2008) p300 (histone acetyltransferase) biomarker
predicts prostate cancer biochemical recurrence and correlates
with changes in epithelia nuclear size and shape. Prostate
68(10):1097–1104
11. Zhang C, Li K, Wei L, Li Z, Yu P, Teng L, Wu K, Zhu J (2007)
p300 expression repression by hypermethylation associated with
tumour invasion and metastasis in oesophageal squamous cell
carcinoma. J Clin Pathol 60(11):1249–1253
12. Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, Deng W (2011)
Quercetin suppresses cyclooxygenase-2 expression and angio-
genesis through inactivation of P300 signaling. PLoS One
6(8):e22934
13. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and
apoptosis in epithelial cells overexpressing prostaglandin endo-
peroxide synthase 2. Cell 83(3):493–501
14. Sayar C, Sayar H, Ozdemir S, Selc¸uk T, Go¨rgu¨lu¨ O, Akbas¸ Y,
Kemal Olgun M (2012) Cyclooxygenase-2 expression and clini-
cal parameters in laryngeal squamous cell carcinoma, vocal fold
nodule, and laryngeal atypical hyperplasia. Head Neck. doi:
10.1002/hed.22911
15. Sun X, Ge R, Dong Q, Zheng C (2005) The expression of
cyclooxygenase-2 in laryngeal squamous cell carcinoma and its
relationship with MVD. Lin Chuang Er Bi Yan Hou Ke Za Zhi
19(21):967–970
16. Turnell AS, Mymryk JS (2006) Roles for the coactivators CBP
and p300 and the APC/C E3 ubiquitin ligase in E1A-dependent
cell transformation. Br J Cancer 95(5):555–560
17. Byun JS, Wong MM, Cui W, Idelman G, Li Q, De Siervi A, Bilke
S, Haggerty CM, Player A, Wang YH, Thirman MJ, Kaberlein JJ,
Petrovas C, Koup RA, Longo D, Ozato K, Gardner K (2009)
Dynamic bookmarking of primary response genes by p300 and
RNA polymerase II complexes. Proc Natl Acad Sci USA
106(46):19286–19291
18. Guermah M, Palhan VB, Tackett AJ, Chait BT, Roeder RG
(2006) Synergistic functions of SII and p300 in productive acti-
vator-dependent transcription of chromatin templates. Cell
125(2):275–286
19. Janknecht R (2002) The versatile functions of the transcriptional
coactivators p300 and CBP and their roles in disease. Histol
Histopathol 17(2):657–668
20. Liao ZW, Zhou TC, Tan XJ, Song XL, Liu Y, Shi XY, Huang
WJ, Du LL, Tu BJ, Lin XD (2012) High expression of p300 is
linked to aggressive features and poor prognosis of Nasopha-
ryngeal Carcinoma. J Transl Med 10(1):110
21. Li Y, Yang HX, Luo RZ, Zhang Y, Li M, Wang X, Jia WH
(2011) High expression of p300 has an unfavorable impact on
survival in resectable esophageal squamous cell carcinoma. Ann
Thorac Surg 91(5):1531–1538
22. Chen YF, Chen FJ, Yang AK, Zeng ZY, Song M, Li QL (2004)
Clinical characteristics and multivariate analysis of prognostic
factors in recurrent laryngeal carcinoma]. Ai Zheng 23(5):
584–588
23. Meyer S, Fuchs TJ, Bosserhoff AK, Hofsta¨dter F, Pauer A, Roth
V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg
K, Moch H, Landthaler M, Vogt T, Wild PJ (2012) A seven-
marker signature and clinical outcome in malignant melanoma: a
large-scale tissue-microarray study with two independent patient
cohorts. PLoS One 7(6):e38222
24. Chang BW, Kim DH, Kowalski DP, Burleson JA, Son YH,
Wilson LD, Haffty BG (2004) Prognostic significance of cyclo-
oxygenase-2 in oropharyngeal squamous cell carcinoma. Clin
Cancer Res 10(5):1678–1684
25. Park BW, Park S, Park HS, Koo JS, Yang WI, Lee JS, Hwang H,
Kim SI, Lee KS (2012) Cyclooxygenase-2 expression in prolif-
erative Ki-67-positive breast cancers is associated with poor
outcomes. Breast Cancer Res Treat 133(2):741–751
26. Atula T, Hedstro¨m J, Ristima¨ki A, Finne P, Leivo I, Markkanen-
Leppa¨nen M, Haglund C (2006) Cyclooxygenase-2 expression in
squamous cell carcinoma of the oral cavity and pharynx: asso-
ciation to p53 and clinical outcome. Oncol Rep 16(3):485–490
27. Shah S, Prasad S, Knudsen KE (2012) Targeting pioneering
factor and hormone receptor cooperative pathways to suppress
tumor progression. Cancer Res 72(5):1248–1259
28. Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L, Liu L, Xie F,
Kang T, Huang W, Deng W (2012) Simultaneous modulation of
COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit
proliferation and induce apoptosis in breast cancer cells. J Pineal
Res. doi:10.1111/j.1600-079X.2012.00973.x
29. Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Tanaka S,
Kuroiwa K, Eto M, Naito S (2012) p300 mediates cellular
resistance to doxorubicin in bladder cancer. Mol Med Report
5(1):173–176
30. Wang YH, Wu MW, Yang AK, Zhang WD, Sun J, Liu TR, Chen
YF (2011) COX-2 Gene increases tongue cancer cell proliferation
and invasion through VEGF-C pathway. Med Oncol 28(Suppl
1):S360–S366
Eur Arch Otorhinolaryngol (2013) 270:1009–1017 1017
123
